Table 1 Patients’ demographics and clinical characteristics
Pooled placebo (n=6) N (%) | 40 mg q.d. (n=6) N (%) | 40 mg b.i.d. (n=6) N (%) | 40 mg t.i.d. (n=6) N (%) | P | |
|---|---|---|---|---|---|
Ethnic origin, n (%) | |||||
Caucasian | 4 (66.6) | 3 (50.0) | 2 (33.3) | 2 (33.3) | 0.604a |
African American | 0 (0.0) | 2 (33.3) | 3 (50.0) | 2 (33.3) | |
Hispanic | 2 (33.3) | 1 (16.6) | 1 (16.6) | 1 (16.6) | |
Asian | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.6) | |
Gender, n (%) | 0.262a | ||||
Male | 5 (83.3) | 2 (33.3) | 3 (50.0) | 2 (33.3) | |
Female | 1 (16.6) | 4 (66.6) | 3 (50.0) | 4 (66.6) | |
Age (year), mean (s.d.) | 28.20 (4.75) | 34.00 (3.50) | 38.50 (12.94) | 40.50 (9.92) | 0.098b |
MADRS total score at screening, mean (s.d.) | 25.20 (2.93) | 26.00 (3.35) | 26.83 (2.64) | 24.83 (2.56) | 0.636b |
